Drug hypersensitivity syndrome: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms);Syndrome d'hypersensibilité médicamenteuse ou DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)

Annales de Dermatologie et de Venereologie

Volumn 131, Issue 3, 2004, Pages 293-297

  Begon, E ^a   Roujeau, J C ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; ANTITHYROID AGENT; CARBAMAZEPINE; CORTICOSTEROID; DAPSONE; FLUINDIONE; GABAPENTIN; IMMUNOGLOBULIN; LAMOTRIGINE; MINOCYCLINE; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; SALAZOSULFAPYRIDINE; SULFONAMIDE; THALIDOMIDE; ZALCITABINE;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOM; EOSINOPHILIA; ERYTHRODERMA; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; INCIDENCE; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LYMPHADENOPATHY; MYOCARDITIS; PERICARDITIS; PSEUDOLYMPHOMA; PUSTULOSIS; REVIEW; STEVENS JOHNSON SYNDROME; VIRUS INFECTION;

EID: 1942466648     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(04)93600-9     Document Type: Article

References (42)

1. Coope R, Burrows R. Treatment of epilepsy with sodium diphenyl hydantoine. Lancet 1940;i:490-2.
2. Saltztein S, Ackermann L. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959;12:164-82.
3. Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O, Souteyrand P, Morel P, Dubertret L, Avril MF, Revuz J. Drug induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996;132:1315-21.
4. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.
5. Singer JZ, Wallace SL The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
6. Kaur S, Sarkar R, Thami GP, Kanwar AJ. Anticonvulsant hypersensitivity syndrome. Pediatr Dermatol 2002;19:142-5.
7. Tomecki KJ, Catalano CJ. Dapsone hypersensitivity. The sulfone syndrome revisited. Arch Dermatol 1981;117:38-9.
8. Antunes A, Davril A, Trechot P, Grandidier M, Truchetet F, Cuny JF. Syndrome d'hypersensibilité à la minocycline. Ann Dermatol Venereol 1999;126:518-21.
9. Bonnetblanc JM. Le syndrome d'hypersensibilité médicamenteuse: à la recherche de son identité. Ann Dermatol Venereol 1998;125:309-10.
10. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997;49:542-6.
11. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-4.
12. Warmock JK, Morris DW. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 2002;3:329-39.
13. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
14. Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991;127:1361-4.
15. Parneix Spake A, Bastuji-Garin S, Lobut JB, Erner J, Guyet-Rousset P, Revuz J, et al. Minocycline as a possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol 1995;131:490-1.
16. Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000;95:560-1.
17. Mitchell MC, Boitnott JK, Arregui A, Maddrey WC. Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 1981;71:733-5.
18. Hogg RJ, Sawyer M, Hecox K, Eigenbrodt E. Carbamazepine-induced acute tubulointerstitial nephritis. J Pediatr 1981;98:830-2.
19. Guillon JM, Joly P, Autran B, Denis M, Akoun G, Debre P, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 1992;117:476-8.
20. Engel JN, Mellul VG, Goodman DB Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med 1986;81:928-30.
21. Gupta A, Eggo MC, Uetrecht JP, Cribb AE, Daneman D, Prieder MJ, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992;5:56-67.
22. Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology 1997;49:1442-4.
23. Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, et al. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 2001;285:1153-4.
24. Colvin JH, Sheth AP. Minocycline hypersensitivity syndrome with hypotension mimicking septic shock. Pediatr Dermatol 2001;18:295-8.
25. Fujino Y, Nakajima M, Inoue H, Kusuhara T, Yamada T. Human herpes virus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 2002;51:771-4.
26. Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, et al. Severe hypersensitivity syndrome due to sulfalasazine associated with reactivation of human herpes virus 6. Arch Dermatol 1998;134:1113-7.
27. Dijen V, Bocquet H, Dupuy A, Revuz J, Roujeau JC. Sémiologie et marqueurs de sévèrité des toxidermies érythé mateuses. Ann Dermatol Venereol 1999;126:247-50.
28. Clay PG The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14.
29. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun-Vignes B, et al. Association of human herpes virus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
30. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpes virus 6 infection as a risk factor for the developpment of severe drug-induced hypersensitivity syndrome. Arch Dermatol 2000;136:1108-12.
31. Tohyama M, Hashimoto K. Drug hypersensitivity syndrome and human herpesvirus 6 reactivation. Arch Dermatol 2002;138:268-9.
32. Aihara M, Sugita Y, Takahashi S, Nagatani T, Arata S, Takeuchi K, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001;144:1231-4.
33. Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F, Ranger-Rogez S, et al. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br J Dermatol 2003;148:1032-4.
34. Regnier S, Descamps V, Boui M, Lebrun-Vignes B, Descamps D, Grossin M, et al. Primoinfection à Parvovirus B19 mimant un syndrome d'hypersensibilité médicamenteuse Ann Dermatol Venereol 2000;127:505-6.
35. Kosseian-Bal I, Bocquet H, Beneton N, Encaoua R, Deforges L, Roujeau JC, et al. Syndrome d'hypersensibilité durant une infection à Mycoplasma pneumoniae. Ann Dermatol Venereol 1998;125:328-30.
36. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91.
37. Eliaszewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S, et al. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 2002;47:40-6.
38. Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-68.
39. Choquet-Kastylevsky G, Intrator L, Chenal C, Bocquet H, Revuz J, Roujeau JC. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998;139:1026-32.
40. Tas S, Simonart T. Management of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS Syndrome): An Update. Dermatology 2003;206:353-6.
41. Morand JJ, Lightburn E, Coton T, Carre D, Chouc C, Debonne JM, et al. Syndrome d'hypersensibilité médicamenteuse rapidement résolutif après perfusion d'immunoglobulines humaines. Ann Dermatol Venereol 2001;128:1351-3.
42. Beneton N, Bocquet H, Cosnes A, Revuz J, Roujeau JC. Benefit-risk assessment of acne therapies. Lancet 1997;349:1252.